Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

53.27 +0.39 (+0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
KDMN Stock: 6 Things to Know About Biopharma Kadmon Holdings as Shares Skyrocket
Kadmon Holdings (KDMN) stock is rising higher on Wednesday following news of a deal with Sanofi (SNY) that comes to $1.9 billion. 
Via InvestorPlace
Kadmon Stock Hits 5-Year High On Sanofi's $1.9 Billion Takeover
Sanofi said Wednesday it will spend $1.9 billion to acquire small biotech Kadmon Holdings, and KDMN stock rocketed to a five-year high. 
Via Investor's Business Daily
Why Kadmon Holdings Stock Is Rocketing Higher Today
Sanofi adds another bolt-on acquisition in what is turning out to be a busy year for the French pharma titan. 
Via The Motley Fool
Sanofi's $1.9 Billion Bet On Kadmon: What You Need to Know
Underlining the focus on inorganic growth, French pharma giant Sanofi (NASDAQ: SNY) announced a big-ticket acquisition just a month after another billion-dollar... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot
GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The... 
Via Benzinga
Exposures COVID-19
Pfizer's Abrocitinib Beats Dupixent Late-stage Eczema Trial
Pfizer Inc (NYSE: PFE) announced topline data from the JADE DARE Phase 3 trial comparing abrocitinib with Sanofi SA (NASDAQ: SNY) - Regeneron... 
Via Benzinga
Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis
A Phase 3 trial evaluating Dupixent (dupilumab) for treating children aged 6 months to 5 years with moderate-to-severe atopic dermatitis met its primary and secondary... 
Via Benzinga
Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now
The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet. 
Via The Motley Fool
Exposures COVID-19
Roche's Arthritis Drug, Used As COVID-19 Treatment, Faces Supply Shortage
Roche Holdings AG's (OTCQX: RHHBF) drug Actemra, or tocilizumab, was granted FDA emergency use authorization for critically ill COVID-19 patients after... 
Via Benzinga
Exposures COVID-19 Product Safety
Inside Sanofi's $3.2B Translate Bio Buyout
Before the $3.2 billion acquisition of mRNA player Translate Bio Inc (NASDAQ: TBIO) earlier this month, Sanofi SA (NASDAQ: SNY) expressed interest... 
Via Benzinga
Unusual Options Activity Insight: Sanofi
Sanofi (NASDAQ:SNY) shares experienced unusual options activity on Monday. The stock price moved up to $51.84 following the option alert. Sentiment: BULLISH Option Type: SWEEP... 
Via Benzinga
What Rinvoq's Positive News Means for AbbVie
If the drug can overcome JAK inhibitor-class concerns, it could capture share in the growing atopic dermatitis market. 
Via The Motley Fool
Drug Makers Overseas Are Gaining A Competitive Advantage In The Antibiotics R&D Market; Acurx Pharmaceuticals Ibezapolstat Program Is Helping Level The Field (NASDAQ: ACXP)
Via AB Newswire
FDA Approves Sanofi's Enzyme Therapy For Late-Onset Pompe Disease
The 
Via Benzinga
Exposures Product Safety
Stock Market Rally Hits Highs Amid Strong Earnings, Jobs; Square, GM, Etsy Among Key Movers
The Dow, S&P 500 and Nasdaq amid heavy earnings and a hot jobs report. Square, GM and Etsy were notable movers. 
Via Investor's Business Daily
Topics Stocks
Exposures Fossil Fuels US Equities
Exicure Shares Interim Cavrotolimod Data From Early-Stage Trial In Solid Tumor Patients
Exicure Inc (NASDAQ: XCUR) has reported interim results from Phase 1b/2 trial evaluating cavrotolimod (AST-008) in patients with advanced or metastatic solid... 
Via Benzinga
Sanofi - Regeneron's Libtayo/Chemo Treatment Improves Overall Survival First-Line Lung Cancer
The Phase 3 trial of Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo in combination with platinum-doublet chemotherapy... 
Via Benzinga
How This Historic FDA Approval Benefits Viatris
Here's what the FDA's approval of Semglee, from Viatris and Biocon, means for the former. 
Via The Motley Fool
Exposures Product Safety
Why Translate Bio Stock Soared Today
The biotech is being bought for $3.2 billion. 
Via The Motley Fool
Mid-Afternoon Market Update: Dow Jumps Over 200 Points; Neuronetics Shares Plunge
Toward the end of trading Tuesday, the Dow traded up 0.64% to 35,059.40 while the NASDAQ rose 0.34% to 14,731.57. The S&P also rose, gaining 0.65% to 4,415.65. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Translate Bio Stock Rockets As Sanofi Jumps Into mRNA Technology With $3.2 Billion Takeover
Sanofi is jumping into the messenger RNA game with the $3.2 billion acquisition of Translate Bio, leading TBIO stock to soar Tuesday. 
Via Investor's Business Daily
Exposures COVID-19
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Sanofi Acquires Translate Bio For $38 Per Share In Cash Or $3.2B
Sanofi has entered into a definitive agreement with Translate Bio for $38.00 per share in cash, which represents a total equity value of $3.2B a fully diluted basis. 
Via Talk Markets
Sanofi Bets Big On mRNA Push With Translate Bio Acquisition For $3.2B: Highlights
A year after paying Translate Bio Inc (NASDAQ: TBIO) a whopping $425 million to develop mRNA vaccines for infectious diseases, including COVID-19, Sanofi... 
Via Benzinga
Exposures COVID-19
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi... 
Via Benzinga
Sanofi (SNY) Q2 2021 Earnings Call Transcript
SNY earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.